Ipca Laboratories is trading higher by 3% at Rs 694, extending its previous day’s 2% gain in otherwise weak market, after reporting over 400 bps year on year (yoy) improvement in EBITDA or operating margins at 27.70% for the quarter ended September 2013 (Q2) against 23.28% in year ago quarter.
The company’s net profit during the quarter under review however, grew marginally by 3% at Rs 129 crore on yoy basis, mainly on account of forex loss of Rs 40 crore. The pharmaceutical company had profit of Rs 125 crore in the same quarter year ago. Net total income up 10% at Rs 852 crore on yoy basis, Ipca Laboratories said in a statement.
Analyst at Angel Broking recommends an “Accumulate” on the stock with a price target of Rs 724.
The stock opened at Rs 677 and touched high of Rs 696 on BSE. A combined around 263,000 shares have changed hands on the counter till early noon deals on BSE and NSE.
The company’s net profit during the quarter under review however, grew marginally by 3% at Rs 129 crore on yoy basis, mainly on account of forex loss of Rs 40 crore. The pharmaceutical company had profit of Rs 125 crore in the same quarter year ago. Net total income up 10% at Rs 852 crore on yoy basis, Ipca Laboratories said in a statement.
Analyst at Angel Broking recommends an “Accumulate” on the stock with a price target of Rs 724.
The stock opened at Rs 677 and touched high of Rs 696 on BSE. A combined around 263,000 shares have changed hands on the counter till early noon deals on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%